- 1Unilever grew underlying sales 4.8% in H1 2026, 4.2 points from volume and 0.6 from price; the shares rose 8.45% on results day.
- 2Ice cream was demerged in December 2025 and Foods is being combined with McCormick ($44.8bn, by mid-2027), leaving a pure home and personal care company.
- 3The guide calls for a second half of 4-5% growth led by pricing, which implies price rising to roughly 2-3% while volume slows to about 2%.
- 4The Handoff Test scores that switch on the October 28 Q3 statement: price at least +1.5%, volume at least +2.0%, USG inside the band, guide held.
- 5Emerging markets (7.0%) and Power Brands (6.0%) carry the growth; developed markets grew 1.5% and Europe shrank.
Strengths
- H1 USG 4.8%, 4.2 pts from volume
- Power Brands +6.0%
- Emerging markets +7.0%, India +8%
- Margin 20.3%, €6bn buybacks to 2029
Weaknesses
- Developed markets +1.5%, Europe −0.9%
- Turnover +0.5% after currency
- Home Care margin only 15.8%
- Price just +0.6% in H1
Opportunities
- Pure-play HPC after Foods deal
- Dr. Squatch, Wild, Grüns
- India volume-led growth
- Beauty & Wellbeing +8.1% in Q2
Threats
- Volume loss as price rises
- L'Oréal in premium beauty
- McCormick deal + stake sales
- Emerging-market currencies
Unilever spent 2025 and 2026 taking itself apart. Ice cream (Magnum, Ben & Jerry's, Wall's) left in December 2025, and in March 2026 Unilever agreed to combine its Foods business (Knorr, Hellmann's) with McCormick in a $44.8 billion deal. What is left by mid-2027 is a pure home and personal care company. While that was happening, the remaining business had its best stretch in years: underlying sales grew 4.8% in the first half of 2026, 4.2 points of it from volume, and the shares rose 8.45% on results day, July 28.
The awkward part is the guidance. Unilever says the second half will grow 4-5%, "led by pricing", after a first half in which price contributed just 0.6 points. This SWOT analysis covers the strengths, weaknesses, opportunities and threats of the new Unilever, and sets up one test for the Q3 trading statement on October 28, 2026: can volume hand the growth over to price without stalling?
Unilever at a Glance
| Metric | Value | Source |
|---|---|---|
| FY2025 underlying sales growth (USG) | 3.5% (volume 1.5%, price 2.0%) | FY2025 results (Feb 12, 2026) |
| FY2025 turnover / underlying operating margin | €50.5bn (−3.8%) / 20.0% | FY2025 results |
| Q1 2026 USG | 3.8% (volume 2.9%, price 0.9%) vs ~3.7% consensus | Q1 2026 trading statement (Apr 30, 2026) |
| H1 2026 USG | 4.8% (volume 4.2%, price 0.6%) | H1 2026 results (Jul 28, 2026) |
| Q2 2026 USG | 5.8% (volume 5.5%, price 0.2%) | H1 2026 results |
| H1 2026 turnover / margin / underlying EPS | €25.6bn (+0.5%) / 20.3% (+10bps) / €1.61 (+2.4%) | H1 2026 results |
| Power Brands (30 brands), H1 USG | 6.0% (volume 5.4%) | H1 2026 results |
| Emerging / developed markets, H1 USG | 7.0% / 1.5% | H1 2026 results |
| 2026 buyback / 2026-2029 plan | €1.5bn (completed Jun 5) / €6bn | H1 2026 results |
| Q3 2026 trading statement | October 28, 2026 | Unilever financial calendar |
What Unilever Is Now
Older Unilever SWOT analyses describe a company that no longer exists. Four changes matter:
| Change | Date | What it means |
|---|---|---|
| The Magnum Ice Cream Company demerged | Completed Dec 6, 2025 | Ice cream is gone; Unilever kept a 19.85% stake (fair value €1,852m) to sell down within up to five years |
| Foods combined with McCormick | Announced Mar 31, 2026 | Reverse Morris Trust valuing Foods at $44.8bn (~13.8x EV/EBITDA); Unilever shareholders get 55.1% of the new company, Unilever 9.9% plus $15.7bn cash; completion by mid-2027 (Wachtell Lipton) |
| Premium bolt-ons | 2025-2026 | Wild (refillable deodorant, 2025), Dr. Squatch (men's grooming, agreed June 2025), 80% of Grüns (greens supplements, €767m, 2026) |
| Productivity programme | Completed by H1 2026 | The €800m plan announced in March 2024 (about 7,500 roles) finished ahead of schedule |
Leadership changed too. Fernando Fernandez has been CEO since March 1, 2025, Srinivas Phatak is CFO, and Ian Meakins succeeded Nils Andersen as chair. Nelson Peltz is still on the board; he was re-elected at the May 13, 2026 AGM.
The Four Business Groups in H1 2026
| Business group | H1 USG | Volume | Price | Margin (UOM) | Q2 USG |
|---|---|---|---|---|---|
| Beauty & Wellbeing | 5.9% | 4.5% | 1.3% | 19.5% | 8.1% |
| Personal Care | 4.8% | 4.1% | 0.7% | 22.2% | 5.9% |
| Home Care | 7.6% | 7.4% | 0.2% | 15.8% | 9.1% |
| Foods (leaving) | 1.2% | 1.2% | 0.0% | 23.3% | 0.2% |
Source: H1 2026 results. Two things stand out. Home Care grew 7.6% almost entirely on volume, at the lowest margin in the group. And Foods, the highest-margin business, grew least: the part Unilever is selling is the part that was dragging the top line.
The Handoff Test
Here is the arithmetic that makes the second half interesting. Unilever guides 2026 USG within 4-6% with about 3% volume, and the second half at 4-5%, led by pricing. After 4.2% volume in the first half, a full year near 3% implies second-half volume of roughly 2%, so second-half price has to rise to roughly 2-3%, from 0.6% in H1 and 0.2% in Q2. That is our calculation from the guidance, not a figure Unilever has published. The H1 release does not say what will drive the pricing.
That is a handoff: the growth engine switches from volume to price in one quarter. Handoffs are where consumer-goods stories break. Raise prices too fast and volume falls further than planned; raise them too slowly and growth drops below the range. The Handoff Test scores it on the Q3 statement and every print after it. Its shape follows the design rules from our earlier earnings retrospectives: one variable per signal, weights, gaps rather than levels, a "not yet taken" state, and a forward-guide line.
| # | Signal (weight) | Passes if | Fails if | Not yet taken if |
|---|---|---|---|---|
| 1 | Price picks up (30%) | Q3 group price ≥ +1.5% | Below +1.0% | — |
| 2 | Volume holds (25%) | Q3 group volume ≥ +2.0% | Below +1.0% | — |
| 3 | USG inside the H2 band (15%) | Q3 USG ≥ 4.0% | Below 3.5% | — |
| 4 | Full-year guide (20%) | 4-6% USG and ~3% volume reaffirmed or raised | USG or volume guide cut | Volume guide not restated |
| 5 | Emerging markets carry (10%) | EM USG ≥ 6% | Below 5% | EM figure not given in the statement |
Why these bars: signal 1 needs price to step up by more than a point from Q2, about half the second-half requirement in the first of two quarters. Signal 2 allows volume to fall from 5.5% to 2% before it fails, because that fall is in the guidance; a print below 1% would mean the price increases are costing more volume than planned. Signal 3 uses a band against the guide rather than a sign, and signal 4 is the forward line, because in the retrospectives we have run so far the guide has moved the stock more often than the quarter.
What would falsify it: the test assumes the second-half price increase is a choice Unilever is making. If Q3 shows price above 2% and volume above 4%, the test was asking the wrong question: demand would be strong enough to take both, and the guide was conservative, not a handoff.
Q3 2026 Earnings Preview: October 28
As published on October 19, 2026, nine days before the statement:
| Item | Q2 2026 | Q1 2026 | What to read first |
|---|---|---|---|
| USG | 5.8% | 3.8% | Whether Q3 lands in the 4-5% H2 band |
| Volume | 5.5% | 2.9% | How far below Q2 it falls |
| Price | 0.2% | 0.9% | Whether it clears +1.5% |
| Emerging markets | 8.3% | — | India and Indonesia |
Unilever's Q3 statement is sales-only (no profit figures), so the full-year guide wording is the only forward number. We found no published Q3 consensus at the time of writing.
Unilever Strengths
- Volume-led growth: H1 2026 USG of 4.8% came 4.2 points from volume; Q2 volume of 5.5% was the best in more than a decade, according to the company.
- Power Brands: the 30 largest brands (Dove, Vaseline, Persil and others) grew 6.0% in H1, ahead of the group.
- Emerging-market base: emerging markets grew 7.0% in H1 (Q2 8.3%); India grew 8% (Q2 10%), Latin America 7.6% and Indonesia 7%.
- Margin held through the split: underlying operating margin of 20.3% in H1, up 10bps, after 20.0% in 2025.
- Cash returns: a €0.4664 quarterly dividend (+3%), a €1.5bn 2026 buyback completed by June 5, and €6bn planned for 2026-2029.
Unilever Weaknesses
- Developed markets lag: developed markets grew 1.5% in H1 and Europe shrank 0.9%; North America grew 2.7%.
- Currency eats the growth: H1 turnover rose only 0.5% to €25.6bn despite 4.8% USG; in Q1 currency cut turnover by 7.7 points.
- Thin reported earnings growth: underlying EPS rose 2.4% and diluted EPS from continuing operations fell 2.5% in H1.
- Home Care margin: the fastest-growing group earns the lowest margin (15.8%), so the growth mix does not lift group profit much.
- Price has been absent: 0.6 points of price in H1 means the pricing-led second half is untested.
Unilever Opportunities
- Pure-play rerating: after the Foods deal closes (by mid-2027), Unilever becomes a home and personal care company, the business mix of L'Oréal, Colgate and P&G rather than of a food group.
- Premium bolt-ons: Dr. Squatch, Wild and Grüns add faster-growing premium and direct-to-consumer brands in men's grooming, refills and supplements.
- India: Hindustan Unilever grew 10% in its April-June quarter with 5% volume, its best in 13 quarters.
- Beauty & Wellbeing: 8.1% growth in Q2, with supplements now a larger part of the group after Grüns.
Unilever Threats
- Price elasticity: the second-half guide needs price increases in categories where P&G grew organic sales just 1% in its fiscal 2026 and was flat in its April-June quarter.
- Beauty competition: L'Oréal grew like-for-like sales 6.8% in H1 2026, the same premium beauty growth Unilever is buying into.
- Deal execution: the McCormick combination needs approvals and runs into mid-2027; Unilever also has two stakes to sell (19.85% of Magnum, 9.9% of the new food company).
- Currency: emerging-market currencies, where the growth is, keep turning USG into flat euro turnover.
- Ben & Jerry's spillover: the brand's dispute is now mainly with Magnum, but the reputational history stays attached to Unilever's name.
Unilever TOWS Matrix
| Opportunities | Threats | |
|---|---|---|
| Strengths | SO: Use emerging-market distribution to scale the new premium brands (Dr. Squatch, Grüns) beyond the U.S. | ST: Use Power Brands' volume momentum to take price selectively, brand by brand, rather than across the portfolio. |
| Weaknesses | WO: Use the Foods proceeds and the pure-play focus to fix developed-market growth, starting in Europe. | WT: If Q3 volume falls below 1%, slow the price increases before the McCormick deal and stake sales compete for attention. |
For a step-by-step way to rank these moves, see how to turn a SWOT into a TOWS matrix.
Related Analysis
- Unilever SWOT example: the four quadrants in one grid, with TOWS strategies
- Procter & Gamble SWOT analysis 2026: the largest home and personal care rival
- L'Oréal SWOT: the benchmark for the beauty business Unilever is building
- General Mills SWOT analysis 2026: a price reset in packaged food, scored print by print
Want to run this kind of strategic diagnostic yourself? Try SWOTPal free — paste a company name or upload an annual report and get a SWOT plus TOWS strategies in minutes.
Generate a professional, cited SWOT with the AI Agent — for any company or topic.